Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma

Metastatic melanoma refractory to checkpoint inhibitors is a challenging clinical scenario. We present the case of a patient who was refractory to standard of care but was able to achieve a durable complete remission with the combination of stereotactic body radiation therapy (SBRT), talimogene lahe...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfe, Zachary, Blackham, Aaron, McIntosh, Alyson, Miller, Angela, Sheikh, Hina, Nair, Suresh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596194/
https://www.ncbi.nlm.nih.gov/pubmed/36312666
http://dx.doi.org/10.7759/cureus.29573
_version_ 1784815815684521984
author Wolfe, Zachary
Blackham, Aaron
McIntosh, Alyson
Miller, Angela
Sheikh, Hina
Nair, Suresh
author_facet Wolfe, Zachary
Blackham, Aaron
McIntosh, Alyson
Miller, Angela
Sheikh, Hina
Nair, Suresh
author_sort Wolfe, Zachary
collection PubMed
description Metastatic melanoma refractory to checkpoint inhibitors is a challenging clinical scenario. We present the case of a patient who was refractory to standard of care but was able to achieve a durable complete remission with the combination of stereotactic body radiation therapy (SBRT), talimogene laherparepvec (TVEC), and ipilimumab.
format Online
Article
Text
id pubmed-9596194
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-95961942022-10-28 Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma Wolfe, Zachary Blackham, Aaron McIntosh, Alyson Miller, Angela Sheikh, Hina Nair, Suresh Cureus Oncology Metastatic melanoma refractory to checkpoint inhibitors is a challenging clinical scenario. We present the case of a patient who was refractory to standard of care but was able to achieve a durable complete remission with the combination of stereotactic body radiation therapy (SBRT), talimogene laherparepvec (TVEC), and ipilimumab. Cureus 2022-09-25 /pmc/articles/PMC9596194/ /pubmed/36312666 http://dx.doi.org/10.7759/cureus.29573 Text en Copyright © 2022, Wolfe et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Wolfe, Zachary
Blackham, Aaron
McIntosh, Alyson
Miller, Angela
Sheikh, Hina
Nair, Suresh
Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
title Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
title_full Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
title_fullStr Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
title_full_unstemmed Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
title_short Durable Complete Remission With Combination of Stereotactic Body Radiation Therapy (SBRT) and Talimogene Laherparepvec (TVEC) Followed by Ipilimumab in Refractory Metastatic Melanoma
title_sort durable complete remission with combination of stereotactic body radiation therapy (sbrt) and talimogene laherparepvec (tvec) followed by ipilimumab in refractory metastatic melanoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596194/
https://www.ncbi.nlm.nih.gov/pubmed/36312666
http://dx.doi.org/10.7759/cureus.29573
work_keys_str_mv AT wolfezachary durablecompleteremissionwithcombinationofstereotacticbodyradiationtherapysbrtandtalimogenelaherparepvectvecfollowedbyipilimumabinrefractorymetastaticmelanoma
AT blackhamaaron durablecompleteremissionwithcombinationofstereotacticbodyradiationtherapysbrtandtalimogenelaherparepvectvecfollowedbyipilimumabinrefractorymetastaticmelanoma
AT mcintoshalyson durablecompleteremissionwithcombinationofstereotacticbodyradiationtherapysbrtandtalimogenelaherparepvectvecfollowedbyipilimumabinrefractorymetastaticmelanoma
AT millerangela durablecompleteremissionwithcombinationofstereotacticbodyradiationtherapysbrtandtalimogenelaherparepvectvecfollowedbyipilimumabinrefractorymetastaticmelanoma
AT sheikhhina durablecompleteremissionwithcombinationofstereotacticbodyradiationtherapysbrtandtalimogenelaherparepvectvecfollowedbyipilimumabinrefractorymetastaticmelanoma
AT nairsuresh durablecompleteremissionwithcombinationofstereotacticbodyradiationtherapysbrtandtalimogenelaherparepvectvecfollowedbyipilimumabinrefractorymetastaticmelanoma

Ejemplares similares